{"id":"https://openalex.org/W4393095666","doi":"https://doi.org/10.1158/1538-7445.am2024-6037","title":"Abstract 6037: Copper-67 as a next-generation radioconjugate warhead for cancer therapy","display_name":"Abstract 6037: Copper-67 as a next-generation radioconjugate warhead for cancer therapy","publication_year":2024,"publication_date":"2024-03-22","ids":{"openalex":"https://openalex.org/W4393095666","doi":"https://doi.org/10.1158/1538-7445.am2024-6037"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2024-6037","doi":"https://doi.org/10.1158/1538-7445.am2024-6037","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2024-6037","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059622287","display_name":"Matt Harris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268048","display_name":"Clarity Pharmaceuticals Ltd. (Australia)","ror":"https://ror.org/05jced525","country_code":"AU","type":"company","lineage":["https://openalex.org/I4405268048"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Matt Harris","raw_affiliation_strings":["1Clarity Pharmaceuticals, Sydney, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Clarity Pharmaceuticals, Sydney, Australia;","institution_ids":["https://openalex.org/I4405268048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110435388","display_name":"Kurt R. Gehlsen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268048","display_name":"Clarity Pharmaceuticals Ltd. (Australia)","ror":"https://ror.org/05jced525","country_code":"AU","type":"company","lineage":["https://openalex.org/I4405268048"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Kurt Gehlsen","raw_affiliation_strings":["1Clarity Pharmaceuticals, Sydney, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Clarity Pharmaceuticals, Sydney, Australia;","institution_ids":["https://openalex.org/I4405268048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060118104","display_name":"Lachlan E. McInnes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268048","display_name":"Clarity Pharmaceuticals Ltd. (Australia)","ror":"https://ror.org/05jced525","country_code":"AU","type":"company","lineage":["https://openalex.org/I4405268048"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Lachlan McInnes","raw_affiliation_strings":["1Clarity Pharmaceuticals, Sydney, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Clarity Pharmaceuticals, Sydney, Australia;","institution_ids":["https://openalex.org/I4405268048"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068928963","display_name":"Jason Stuart Lewis","orcid":"https://orcid.org/0000-0001-7065-4534","observed_orcids":["https://orcid.org/0000-0001-7065-4534"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Lewis","raw_affiliation_strings":["2Memorial Sloan Kettering Cancer Center, New York City, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Memorial Sloan Kettering Cancer Center, New York City, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"84","issue":"6_Supplement","first_page":"6037","last_page":"6037"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10782","display_name":"Nanoplatforms for cancer theranostics","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2204","display_name":"Biomedical Engineering"},"field":{"id":"https://openalex.org/fields/22","display_name":"Engineering"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T13561","display_name":"Chemical Reactions and Isotopes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/copper-67","display_name":"copper-67","score":0.9919999837875366},{"id":"https://openalex.org/keywords/radioconjugates","display_name":"radioconjugates","score":0.8220000267028809},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.8370000123977661},{"id":"https://openalex.org/keywords/copper-64","display_name":"copper-64","score":0.8629999756813049},{"id":"https://openalex.org/keywords/prostate-specific-membrane-antigen","display_name":"prostate-specific membrane antigen","score":0.8019999861717224},{"id":"https://openalex.org/keywords/ca19-9","display_name":"CA19-9","score":0.8600000143051147},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.7680000066757202},{"id":"https://openalex.org/keywords/pancreatic-ductal-adenocarcinoma","display_name":"pancreatic ductal adenocarcinoma","score":0.9769999980926514},{"id":"https://openalex.org/keywords/tissue-distribution","display_name":"tissue distribution","score":0.5090000033378601},{"id":"https://openalex.org/keywords/biodosimetry","display_name":"biological dosimetry","score":0.5809999704360962}],"concepts":[{"id":"https://openalex.org/C149617267","wikidata":"https://www.wikidata.org/wiki/Q827512","display_name":"Warhead","level":2,"score":0.6873793601989746},{"id":"https://openalex.org/C2983331546","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer therapy","level":3,"score":0.5414048433303833},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5261473059654236},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.45941126346588135},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3949397802352905},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32830584049224854},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.13758644461631775},{"id":"https://openalex.org/C146978453","wikidata":"https://www.wikidata.org/wiki/Q3798668","display_name":"Aerospace engineering","level":1,"score":0.04965198040008545}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2024-6037","doi":"https://doi.org/10.1158/1538-7445.am2024-6037","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1158/1538-7445.am2024-6037","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W132327977","https://openalex.org/W2037793450","https://openalex.org/W1784267169","https://openalex.org/W3126723600","https://openalex.org/W4411175964","https://openalex.org/W4402384684","https://openalex.org/W1999896158","https://openalex.org/W4416329593","https://openalex.org/W4378086629","https://openalex.org/W4312226954"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"and":[2,25,38,46,60,65,90,133,141,154,189,220,337,384],"Purpose:":[3],"Antibody":[4],"drug":[5],"conjugates":[6,94],"(ADCs)":[7],"have":[8,77],"shown":[9],"promise":[10],"as":[11,397],"cancer":[12,67,403],"treatments.":[13],"However,":[14],"the":[15,79,110,183,256,329,355,382,409],"efficacy":[16,80],"of":[17,73,81,92,101,112,205,238,242,249,262,267,292,297,331,408],"ADCs":[18],"has":[19],"been":[20],"limited":[21],"in":[22,85,95,109,122,207,213,222,376,381],"solid":[23],"tumors":[24,59],"can":[26,39],"come":[27],"with":[28,304,334,358,366],"significant":[29],"toxicities.":[30],"Radioconjugates":[31],"utilize":[32],"various":[33,70,137],"radionuclides":[34,150],"that":[35,352],"are":[36,360,373],"chelated":[37],"be":[40],"conjugated":[41,162],"to":[42,57,63,136,148,163,255,274,278,316,322,346],"small":[43],"molecules,":[44],"peptides":[45],"antibodies.":[47],"We":[48,76,157,327],"propose":[49],"Targeted":[50],"Copper":[51],"Theranostics":[52],"(TCTs)":[53],"which":[54],"use":[55],"copper-64":[56],"image":[58],"beta-emitting":[61],"copper-67":[62,82,102,142,359],"irradiate":[64],"kill":[66],"cells":[68],"using":[69,283,354],"molecular":[71],"targets":[72],"oncological":[74],"relevance.":[75],"evaluated":[78,158],"based":[83],"therapy":[84,404],"three":[86,159],"formats;":[87],"peptides,":[88],"antibodies,":[89],"pre-targeting":[91],"antibody":[93,180],"relevant":[96],"tumor":[97,301,332],"mouse":[98],"models.":[99],"Benefits":[100],"[half-life,":[103],"61.8":[104],"h;":[105],"100%":[106],"\u03b2-":[107],"energy":[108],"range":[111],"0.18-0.56":[113],"MeV]":[114],"include":[115],"high":[116,118,128],"purity,":[117],"specific":[119,175],"activity,":[120],"manufacturing":[121],"a":[123,164,170,190,398],"centralized":[124],"distribution":[125],"model":[126],"at":[127],"yields":[129],"on":[130],"electron":[131],"accelerators,":[132],"half-life":[134],"suitable":[135],"targeting":[138,173,182,197],"formats.":[139],"Copper-64":[140],"provide":[143],"multiple":[144,364,377],"logistical":[145],"benefits":[146],"relative":[147,254],"other":[149],"including":[151],"Ga-68,":[152],"F-18":[153],"Lu-177.":[155],"Methods:":[156],"tumor-targeting":[160],"moieties":[161],"sarcophagine":[165,356],"bifunctional":[166],"chelator":[167,357],"(SAR),":[168],"including:":[169],"peptide":[171],"dimer":[172],"prostate":[174],"membrane":[176],"antigen":[177],"(SAR-bisPSMA);":[178],"an":[179,367],"5B1,":[181],"PDAC-specific":[184],"biomarker":[185],"carbohydrate":[186],"antigen-19-9":[187],"(CA19-9);":[188],"Tz-TCO":[191],"IDEEA":[192],"huA33":[193],"antibody/sarcophagine":[194],"tetrazine":[195],"conjugate":[196],"transmembrane":[198],"glycoprotein":[199],"A33.":[200],"Various":[201],"doses":[202,296],"were":[203],"administered":[204],"[67Cu]Cu-SAR-bisPSMA":[206,250],"LNCAP":[208],"xenografts;":[209],"[67Cu]Cu-SAR-5B1":[210],"(~10":[211],"\u03bcg)":[212],"FC1245":[214],"Ft2Ab":[215],"PDAC":[216],"tumor-bearing":[217],"C57BL/6":[218],"mice;":[219],"[67Cu]Cu-MeCOSAR-Tz":[221,298],"athymic":[223],"nude":[224],"mice":[225,310],"bearing":[226],"A33":[227],"antigen-expressing":[228],"SW1222":[229],"human":[230],"colorectal":[231],"carcinoma":[232],"xenografts":[233],"72":[234],"hours":[235],"after":[236,260],"administration":[237,261],"huA33-TCO.":[239],"Results:":[240],"Administration":[241],"either":[243],"7.5,":[244],"15":[245],"or":[246,286,289],"30":[247],"MBq":[248,266,288,295],"increased":[251],"overall":[252,272,306,343],"survival":[253,273,307,344],"control":[257,279,323],"group.":[258],"Similarly,":[259],"4,":[263],"11,":[264],"18":[265],"[67Cu]Cu-5B1,":[268],"treated":[269,309],"groups":[270],"enhanced":[271,305],"32":[275],"days":[276,315,318],"compared":[277,321,345],"(14":[280],"days).":[281,325],"Pre-targeting":[282],"~18.5,":[284],"37.0":[285],"55.5":[287],"fractionated":[290],"dosing":[291],"two":[293],"27.8":[294],"showed":[299],"efficient":[300],"growth":[302,333],"reduction":[303],"for":[308,402,412],"pre-administered":[311],"huA33-TCO,":[312],"from":[313],"68":[314],">200":[317],"(dose":[319],"dependent)":[320],"(21":[324],"Conclusion:":[326],"report":[328],"inhibition":[330],"minimal":[335],"radiotoxicity":[336],"each":[338],"format":[339],"demonstrated":[340,351],"significantly":[341],"improved":[342],"controls.":[347],"Collectively":[348],"our":[349],"results":[350],"TCTs":[353,372],"effective":[361],"radioconjugates":[362],"across":[363],"formats":[365],"acceptable":[368],"safety":[369],"profile.":[370],"Copper-67-based":[371],"being":[374],"translated":[375],"theranostic":[378],"clinical":[379],"trials":[380],"USA":[383],"Australia.":[385],"Citation":[386],"Format:":[387],"Matt":[388],"Harris,":[389],"Kurt":[390],"Gehlsen,":[391],"Lachlan":[392],"McInnes,":[393],"Jason":[394],"Lewis.":[395],"Copper-67":[396],"next-generation":[399],"radioconjugate":[400],"warhead":[401],"[abstract].":[405],"In:":[406],"Proceedings":[407],"American":[410],"Association":[411],"Cancer":[413,431],"Research":[414],"Annual":[415],"Meeting":[416],"2024;":[417],"Part":[418],"1":[419],"(Regular":[420],"Abstracts);":[421],"2024":[422],"Apr":[423],"5-10;":[424],"San":[425],"Diego,":[426],"CA.":[427],"Philadelphia":[428],"(PA):":[429],"AACR;":[430],"Res":[432],"2024;84(6_Suppl):Abstract":[433],"nr":[434],"6037.":[435]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2024-03-23T00:00:00"}